Sab Biotherapeutics, Inc. (SABS) fundamentals score
Sab Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. Its programs are based on mechanisms of action that have achieved proof-of-concept in clinical trials in indications with significant unmet medical needs.
Biological Products, (No Diagnostic Substances) · Healthcare · Listed on NASDAQ
Overall: 3.2 out of 10, Unhealthy fundamentals
- Growth: 2.0/10
- Profitability: 1.0/10
- Financial health: 4.1/10
- Earnings quality: 7.7/10
- Valuation: 2.9/10
Scores are calculated from Sab Biotherapeutics, Inc.’s SEC filings, using the 12 months through 2024-12. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10